Hepatocellular Carcinoma — Written Clinical Reasoning

SAQ 1 — HCC in a cirrhotic patient: staging and management (15 marks, 30 minutes)

Prompt: Outline your assessment, the staging and diagnostic reasoning, the integrated management plan addressing each problem, and the communication framework. Justify each decision with reference to evidence. [1]

Model Answer

Step 1 — The diagnostic synthesis (3 marks): [1]

This man has a definite hepatocellular carcinoma (HCC) by non-invasive imaging criteria. The multiphase MRI shows the classic triad of arterial phase hyperenhancement, portal venous washout, and an enhancing capsule in a lesion over 2 cm in a cirrhotic liver — this is LI-RADS 5, which is diagnostic of HCC without the need for biopsy [2]. The rising AFP (from 12 to 180 ng/mL) corroborates the diagnosis, though the imaging alone suffices. A biopsy is NOT needed and carries a risk of tumour seeding (1 to 3 percent).

The diagnosis was made through the intended surveillance pathway — six-monthly ultrasound plus AFP detected the lesion early. The Singal 2014 meta-analysis confirmed that surveillance improves early-stage detection, curative treatment rates, and overall survival [3].

Step 2 — The staging (4 marks): [1]

I would stage this patient using the Barcelona Clinic Liver Cancer (BCLC) system, which integrates tumour burden, liver function, and performance status [2][1]:

• Tumour burden: single 4.2 cm lesion, no vascular invasion, no extrahepatic spread. This is early-stage tumour burden.
• Liver function: Child-Pugh A (score 5: bilirubin 18, albumin 36, INR 1.1, no ascites, no encephalopathy). Preserved liver function.
• Performance status: ECOG 0. Fully active. [1]

This places him at BCLC stage A (early) — the curative treatment stage. [1]

However, I must assess his portal pressure to determine the optimal curative modality. His platelet count of 95 x 10^9/L and the presence of small oesophageal varices suggest clinically significant portal hypertension (CSPH), which is a critical determinant: a patient with CSPH is at high risk of post-hepatectomy liver failure and decompensation, and resection becomes less favourable. I would confirm the portal pressure with a hepatic venous pressure gradient (HVPG) if available — a value above 10 mmHg confirms CSPH and shifts the decision toward transplant or ablation rather than resection [2].

Step 3 — The problem list (2 marks): [1]

1. BCLC A hepatocellular carcinoma — the central problem; needs curative therapy.
2. Cirrhosis with clinically significant portal hypertension — complicates resection; needs the portal pressure assessed.
3. Chronic hepatitis C (post-SVR) — the underlying cause; cirrhosis persists despite viral eradication.
4. Type 2 diabetes and hypertension — metabolic comorbidities that complicate surgery and systemic therapy.
5. Small oesophageal varices — need surveillance and possible primary prophylaxis.
6. Psychosocial impact — a new cancer diagnosis on top of chronic liver disease. [1]

Step 4 — The integrated management plan (5 marks): [1]

Pillar 1 — Curative treatment for the HCC: Because he has a single lesion under 5 cm, Child-Pugh A liver function, and BCLC A staging, he is eligible for curative therapy. The choice between resection, ablation, and transplant depends on the portal pressure and the transplant assessment: [1]

• If the HVPG is under 10 mmHg (no CSPH): surgical resection is the first-line option, with a five-year survival of 50 to 70 percent [2].
• If the HVPG is above 10 mmHg (CSPH confirmed): resection is high-risk, and the preferred options are liver transplant (within Milan criteria — he is within them: single lesion under 5 cm, no vascular invasion, no extrahepatic spread) or thermal ablation if the lesion is accessible and transplant is not feasible. Five-year post-transplant survival is around 70 percent with a recurrence rate under 15 percent [2][1].

I would refer him urgently to a multidisciplinary team (MDT) including hepatobiliary surgery, interventional radiology, transplant surgery, and hepatology to determine the optimal curative approach. I would list him for transplant assessment. [1]

Pillar 2 — Management of the underlying liver disease: The cirrhosis is the substrate for the HCC and for future tumours. His HCV is cured (SVR achieved), but the cirrhosis persists. I would ensure he remains under hepatology surveillance. His type 2 diabetes and hypertension need optimisation — metabolic syndrome drives NAFLD/NASH and may contribute to ongoing liver injury. I would screen for and manage his portal hypertension: non-selective beta-blocker (e.g., carvedilol 6.25 mg daily) for primary prophylaxis of variceal bleeding given his small varices and platelet count under 150 [2].

Pillar 3 — Ongoing surveillance: After curative treatment, surveillance continues with six-monthly ultrasound plus AFP for life — the cirrhotic liver can produce new tumours regardless of the treatment of the index lesion. If he receives a transplant, the surveillance shifts to monitoring for recurrence (chest CT, liver imaging, AFP) and for graft complications. [1]

Pillar 4 — Comorbidity management: Optimise his diabetes (HbA1c, glycaemic control) and blood pressure. Assess cardiovascular risk before any surgical intervention. Ensure his nutrition is adequate (sarcopenia is common in cirrhosis and worsens surgical outcomes). [1]

Step 5 — Communication (1 mark): [1]

I would explain the diagnosis in plain language: he has a liver cancer that was caught early by the surveillance programme, which is exactly what surveillance is designed to do. The treatment options — resection, ablation, or transplant — all offer a chance of cure. I would explain why the portal pressure assessment matters (it determines whether surgery is safe), and I would be honest about the lifelong commitment to surveillance. I would involve his GP, the transplant coordinator, the dietitian, and the hepatology nurse specialist, and I would document the shared decisions. [1]